SEC Comment Letter 0000000000-24-010107 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: Sept. 6, 2024 · CIK: 0001671584 · Accession: 0000000000-24-010107
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281892
Letter
September 6, 2024 Marvin L. White Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed August 30, 2024 File No. 333-281892 Dear Marvin L. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Sean Donahue, Esq.
Show Raw Text
September 6, 2024
Marvin L. White
Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed August 30, 2024
File No. 333-281892
Dear Marvin L. White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Sean Donahue, Esq.